Lipid-efficacy RCT · Nat Med 2026
BROOKLYN trial
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.
The bottom line
In patients with heterozygous familial hypercholesterolemia already on maximally tolerated lipid-lowering therapy, adding obicetrapib substantially lowered LDL cholesterol (and improved other lipid parameters) compared with placebo and was well tolerated.
Primary lipid endpoint metUS status: Investigational
At a glance
- Medicine
- Obicetrapib 10 mg daily
- Compared with
- Placebo
- People
- 354
- Who took part
- Patients with heterozygous familial hypercholesterolemia and LDL cholesterol ≥70 mg dl-1 on maximally tolerated lipid-lowering therapy (mean LDL cholesterol 122 mg dl-1, 87% on statins; 190 women, 164 men)
- Design
- Randomized (2:1), presumably double-blind, placebo-controlled trial
- Follow-up
- 365 days
- Main question
- Change in LDL cholesterol from baseline to day 84
Main result
Placebo-adjusted change in LDL cholesterol of -36.3% (95% confidence interval -42.2% to -30.4%, P < 0.0001)
Effect on LDL cholesterol
Placebo-adjusted change in LDL cholesterol of -36.3% (95% CI -42.2% to -30.4%, P < 0.0001)
Other results
At day 84, placebo-adjusted reductions in apolipoprotein B of -24.4%, non-HDL cholesterol of -34.5% and lipoprotein(a) of -45.9%, as well as a placebo-adjusted increase in high-density lipoprotein cholesterol of +138.7%.
Safety
Obicetrapib was well tolerated.
In the trial's own words
“For the primary endpoint, the change in LDL cholesterol from baseline to day 84, obicetrapib treatment resulted in a placebo-adjusted change in LDL cholesterol of -36.3% (95% confidence interval -42.2% to -30.4%, P < 0.0001).”
Quoted from the abstract of Nat Med 2026, checked word for word against PubMed. PubMed 41760952 · Full paper (DOI)
How this medicine works, where it stands and what it costs: Obicetrapib
Common questions
What did the BROOKLYN trial find?
In patients with heterozygous familial hypercholesterolemia already on maximally tolerated lipid-lowering therapy, adding obicetrapib substantially lowered LDL cholesterol (and improved other lipid parameters) compared with placebo and was well tolerated.
Who was in BROOKLYN?
354 people. Patients with heterozygous familial hypercholesterolemia and LDL cholesterol ≥70 mg dl-1 on maximally tolerated lipid-lowering therapy (mean LDL cholesterol 122 mg dl-1, 87% on statins; 190 women, 164 men).
What was BROOKLYN's main result?
Placebo-adjusted change in LDL cholesterol of -36.3% (95% confidence interval -42.2% to -30.4%, P < 0.0001)
How much did LDL cholesterol change in BROOKLYN?
Placebo-adjusted change in LDL cholesterol of -36.3% (95% CI -42.2% to -30.4%, P < 0.0001)
Related trials
- BROADWAY (2025)In high-risk patients already on maximum tolerated lipid-lowering therapy, adding obicetrapib 10 mg daily lowered LDL cholesterol by about 30% more than placebo with a similar rate of adverse events.
- ACCELERATE (2017)Despite markedly improving LDL and HDL cholesterol levels, evacetrapib did not reduce cardiovascular events compared with placebo in high-risk vascular disease patients, and the trial was stopped early for futility.
- REVEAL (2017)Adding the CETP inhibitor anacetrapib to intensive statin therapy modestly reduced major coronary events in patients with atherosclerotic vascular disease, without significant safety concerns.
- dal-OUTCOMES (2012)In patients with a recent acute coronary syndrome, dalcetrapib raised HDL cholesterol but did not reduce cardiovascular events or mortality compared with placebo.
Get your LDL treated to a goal
Preval Health's protocols follow trials like this one. Licensed clinicians set your goal, prescribe and recheck until you reach it.
Get startedEducation only, not medical advice. Results describe the people in this trial and can differ for you. Talk with your clinician before starting or stopping any medicine. Back to all 106 trials.